Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESTRONE vs FLEXERIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (off-label in some contexts),Prostate cancer (palliative therapy, off-label),Breast cancer (palliative therapy in selected cases, off-label)
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Metabolized primarily in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19) and conjugation to glucuronides and sulfates. Estrone is interconvertible with estradiol and estriol. Enterohepatic recirculation occurs.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Approximately 96-98% bound to albumin and sex hormone-binding globulin (SHBG)
~93% bound to plasma proteins, primarily albumin.
0.8-1.2 L/kg; indicates extensive distribution into tissues, particularly adipose tissue.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Oral: ~5% due to extensive first-pass metabolism; Intramuscular: 100%; Topical: variable, approximately 10% systemically.
Oral: ~33% due to extensive first-pass metabolism.
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of metabolites; monitor estrogenic effects.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In Child-Pugh class A or B, reduce dose by 50% and monitor liver function; start at lowest effective dose.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Not indicated for routine use; individualize for rare conditions (e.g., delayed puberty) under specialist guidance. Typical starting dose: 0.3-0.625 mg orally once daily; adjust based on response and bone age.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Start at low end of dosing range (e.g., 0.3-0.625 mg orally once daily); consider increased risk of thromboembolism and endometrial cancer; monitor for adverse effects; use shortest duration possible.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Estrogens increase the risk of endometrial cancer in postmenopausal women. Unopposed estrogen use is associated with increased risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
None
Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction, especially in smokers and older women,Malignancy: Increased risk of endometrial cancer (unopposed estrogen) and potential for breast cancer; avoid use in known or suspected estrogen-dependent neoplasia,Dementia: Possible increased risk in women over 65 years,Gallbladder disease: Increased risk of cholelithiasis,Hypertriglyceridemia: May cause severe hypertriglyceridemia with pancreatitis,Hepatic impairment: Use with caution; may be contraindicated in severe disease,Fluid retention: May exacerbate conditions such as asthma, epilepsy, migraine, cardiac or renal dysfunction,Hypocalcemia: Should be used with caution in patients with hypoparathyroidism,Visual abnormalities: Discontinue if sudden vision loss, proptosis, or migraine develops
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (except in selected palliative cases),Known or suspected estrogen-dependent neoplasia,Active or history of venous thromboembolism (e.g., DVT, pulmonary embolism),Active arterial thromboembolic disease (e.g., stroke, MI),Severe hepatic impairment or disease,Hypersensitivity to estrone or any component of the formulation
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Grapefruit and grapefruit juice may inhibit estrone metabolism, increasing serum levels and risk of adverse effects. Avoid concomitant high-fat meals as they may alter absorption. No other significant food interactions reported. Maintain adequate calcium and vitamin D intake for bone health.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tract abnormalities and potential for other adverse effects. Overall: FDA Pregnancy Category X (contraindicated) unless used for specific conditions like progesterone-resistant recurrent pregnancy loss.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Estrone is excreted in human breast milk; M/P ratio not determined. Use during lactation is generally contraindicated as estrogens may suppress milk production and alter milk composition. Alternative agents recommended if breastfeeding.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
No recommended dosing in pregnancy due to contraindication; if used, no established dose adjustments exist. Estrogen clearance is increased in pregnancy, but systematic data for estrone are lacking; generally, avoidance is advised.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Estrone is primarily used in menopausal hormone therapy and has weak estrogenic activity compared to estradiol. Monitor for endometrial hyperplasia in women with an intact uterus; concurrent progestin is required. Assess thromboembolic risk before initiation. Estrone may be less effective for vasomotor symptoms than estradiol. Avoid in patients with breast cancer, liver disease, or undiagnosed vaginal bleeding.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Take estrone exactly as prescribed; do not alter dose or frequency.,Report any unusual vaginal bleeding, breast lumps, or jaundice immediately.,Estrone does not protect against HIV or other sexually transmitted infections.,You may experience nausea, headache, or breast tenderness; contact your doctor if severe.,Do not use estrone if you are pregnant, think you might be pregnant, or are breastfeeding.,Avoid smoking and excessive alcohol consumption to reduce cardiovascular risks.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
"Almasilate, a magnesium-aluminum antacid, can adsorb estrone in the gastrointestinal tract, reducing its absorption and systemic bioavailability. This interaction may lead to subtherapeutic estrone levels, potentially diminishing its therapeutic effects in hormone replacement therapy. Patients may experience inadequate symptom control or hormonal imbalance if the drugs are taken concomitantly without proper timing separation."
"Clarithromycin is a potent CYP3A4 inhibitor and also inhibits P-glycoprotein, significantly decreasing the clearance of estrone, which is metabolized via CYP3A4 and transported by P-gp. This leads to elevated estrone plasma concentrations, increasing estrogenic effects such as thromboembolic risk, breast tenderness, and endometrial proliferation. Clinical vigilance is warranted, especially in patients on hormone replacement therapy or using estrone for menopausal symptoms, as coadministration may precipitate estrogen-related adverse events."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESTRONE vs FLEXERIL, answered by our medical review team.
ESTRONE is a Estrogen that works by Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.. FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESTRONE and FLEXERIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESTRONE is: For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.. The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESTRONE and FLEXERIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESTRONE is classified as Category C. First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tra. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.